Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy

Cancer

Volumn 88, Issue 2, 2000, Pages 333-343

  Blumenthal, Rosalyn D ^a   Lew, Walter ^a   Juweid, Malik ^a   Alisauskas, Rita ^a   Ying, Zhiliang ^b   Goldenberg, David M ^a  

^a GARDEN STATE CANCER CENTER   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Bone marrow; Chemotherapy; Clinical; Cytokine; FLT3 L; Myelosuppression; Thrombocytopenia

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER GROWTH FACTOR; CYTOTOXIC AGENT; DOXORUBICIN; FLT3 LIGAND; LOMUSTINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; METHOTREXATE; MITOMYCIN; RADIOPHARMACEUTICAL AGENT; STEM CELL FACTOR; TOPOTECAN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CONVALESCENCE; DISEASE SEVERITY; DOSE RESPONSE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SOLID TUMOR; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CYTOKINES; FMS-LIKE TYROSINE KINASE 3; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKOPENIA; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 0034650836     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000115)88:2<333::AID-CNCR13>3.0.CO;2-D     Document Type: Article

References (62)

1. Maxwell M, Maher K. Chemotherapy-induced myelosuppression. Semin Oncol Nurs 1992;8:113-23.
2. Blijham G. Prevention and treatment of organ toxicity during high dose chemotherapy: an overview. Anticancer Drugs 1993;4:527-33.
3. Boesen J, Nooter K, Valerio D. Circumvention of chemotherapy-induced myelosuppression by transfer of the mdr-1 gene. Biotherapy 1993;6:291-302.
4. Testa NG, Hendry GH, Molineux G. Long-term bone marrow damage in experimental systems and in patients after radiation or chemotherapy. Anticancer Res 1985;5:101-10.
5. Sado T, Kamisaku H, Ikarashi Y, Kubo E. Immediate and long-term effects of radiation on the immune system of specific pathogen-free mice. Int J Radiat Biol Relat Stud Phys Chem Med 1988;53:177-87.
6. Meijne EIM, van der Winden-van Groenewegen RJM, Ploemacher RE, Vos O, David JAG, Huiskamp R. The effects of X-irradiation on hematopoietic stem cell compartments in the mouse. Exp Hematol 1991;19:617-23.
7. Lorimore SA, Wright EG. Late effects of X-irradiation on haematopoietic stem cells in CBA/H mice. Int J Radiat Biol 1990;57:385-93.
8. Lord B, Molineaux G, Humphreys E, Stones V. Long term effects of plutonium-239 and radium-224 on haemopoietic progenitor cells and their regulatory microenvironment. Int J Radiat Biol 1991;59:211-8.
9. Grande T, Gaiten S, Tejero C, Bueren JA. Residual hemopoietic damage in adult and 8-day old mice exposed to 7 Gy of X-rays. Int J Radiat Biol 1993;59:59-67.
10. Tavassoli M. Radiosensitivity of stromal cells responsible for in vitro maintenence of hematopoietic stem cells in continuous long-term marrow culture. Exp Hematol 1992;10:435-43.
11. Hall E. Radiobiology for the radiobiologist. New York: Harper and Row, 1978.
12. Jones TD, Morris MD, Young RW. A mathematical model for radiation-induced myelopoiesis. Radiat Res 1991;128:256-66.
13. Eaves C, Cashman J, Eaves A. Methodology of long-term culture of human hematopoietic ells. Tissue Culture Methods 1991;13:55-62.
14. McNiece I, Stewart F, Deacon D, Temeles DS, Zsebo KM, Clark SC, et al. Detection of human CFC with a high proliferative potential. Blood 1989;75:609-12.
15. Lowry P. Hematopoietic stem cell cytokine response. J Cell Biochem 1995;58:410-5.
16. Cooper S, Mantel C, Broxmeyer H. Myelosuppressive effects in vivo with very low dosages of monomeric recombinant murine macrophage inflamatory protein-1a. Exp Hematol 1994;22:186-93.
17. Dunlop D, Wright E, Lorimore S, Graham SJ, Holyoake T, Kerr DJ, et al. Demonstration of stem cell inhibition and myeloprotective effects of Sl/rhMIP1a in vivo. Blood 1992; 79:2221-5.
18. Jacobsen S, Keller J, Ruscetti F, Kondaiah P, Roberts A, Falk L. Bidirectional effects of transforming growth factor b (TGFb) on colony-stimulating factor-induced myelopoiesis in vitro: differential effects of distinct TGFb isoforms. Blood 1991;78:2239-47.
19. Maze R, Sherry B, Kwon B, Cerami A, Broxmeyer H. Myelosuppressive effects in vivo of purified recombinant murine macrophage inflammatory protein 1a. J Immunol 1992;149: 1004-9.
20. Mayani H, Guilbert L, Janowska-Wiesczorek A. Biology of the hematopoietic microenvironment. Eur J Haematol 1992; 49:225-33.
21. Cannistra S, Griffin J. Regulation of the production and function of granulocytes and monocytes. Semin Hematol 1988;25:173-88.
22. Becker A, McCulloch E, Siminovich L, Till J. The effect of differing demands for blood cell production on DNA synthesis by hemopoietic colony-forming cells of mice. Blood 1965;26:296-304.
23. Sallerfors B, Olofsson T. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in serum during induction treatment of acute leukemia. Br J Hematol 1991;78:343-51.
24. Baiocchi G, Scambia G, Benedetti P, Menichella G, Testa V, Pierelli L, et al. Autologous stem cell transplantation: sequential production of hematopoietic cytokines underlying granulocyte recovery. Cancer Res 1996;51:1297-1303.
25. Chen Y, Whang-Peng J, Ming-Lu J, et al. Serum cytokine level fluctuations in chemotherapy-induced myelosuppression. Jpn J Clin Oncol 1996;26:18-23.
26. Brasel K, McKenna H, Morrissey P, Charrier K, Morris AE, Lee CC, et al. Hematologic effects of flt-3 ligand in vivo in mice. Blood 1996;88:2004-12.
27. Lisovsky M, Braun S, Ge Y, Takahira H, Lu L, Savchenko VG, et al. Flt3-ligand production by human bone marrow stromal cells. Leukemia 1996;10:1012-8.
28. Juweid M, Zhang C, Blumenthal R, Sharkey RM, Dunn R, Dunlop D, et al. Factors influencing hematologic toxicity of radioimmunotherapy with 131I-labeled anti-carcinoembryonic antigen antibodies. Cancer 1997;80:2749-53.
29. Siegel J, Wessels B, Watson E, Stabin M, Vriesendorp H, Bradley E. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm 1990;3: 213-33.
30. Fisher D. Radiation dosimetry for radioimmunotherapy. Cancer 1994;73:905-11.
31. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689-94.
32. Loevinger R, Berman M. A revised scheme for calculating the absorbed dose from biologically distributed radionuclide. MIRD pamphlet 1. Soc Nucl Med 1976.
33. Cloutier R, Watson E, Rohrer R. Calculating the radiation dose to an organ. J Nucl Med 1973;14:53-5.
34. Simel D, Gregory P, Matchar D. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol 1991;44:763-70.
35. Vriesendorp HM, Quadri SM, Andersson BS, Dicke KA. Hematologic side effects of radiolabeled immunoglobulin therapy. Exp Hematol 1996;24:1183-90.
36. Meredith RF, Khazaeli MB, Liu T, Plott G, Wheeler RH, Russell C, et al. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 1992;33:1648-53.
37. Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S, et al. Treatment of hormone refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res 1996;2:1289-97.
38. Welt S, Divgi C, Kemeny N, Finn RD, Scott AM, Graham M, et al. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1994;12:1561-71.
39. Sgouros G, Divgi C, Scott A, Williams J, Larson, SM. Hematologic Toxicity in radioimmunotherapy: an evaluation of different predictive measures. J Nucl Med 1996;37:43P.
40. Breitz HB, Fisher DR, Wessels B. Correlation of bone marrow absorbed dose estimates with marrow toxicity. Tumor Targeting 1996;2:173-4.
41. Esik O, Rajtar M, Naszaly A. Bone marrow (reticuloendothelial system) scintigraphy for hematological follow-up of radiochemotherapy-treated patients. Oncology 1993;50:298-302.
42. Jamar F, Field C, Leners N, Ferrant A. Scintigraphic evaluation of haemopoietic bone marrow using a 99mTc-antigranulocyte antibody: a validation study with 52Fe. Br J Hematol 1995;90:22-30.
43. Spangrude G. Hematopoietic stem-cell differentiation. Curr Opin Immunol 1991;3:171-8.
44. Bernstein I, Andrews R, Rowley S. Isolation of human hematopoietic stem cells. Blood Cells 1994;20:15-23.
45. Hestdal K, Ruscetti F, Ihle J, Jacobsen SE, Dubois CM, Kopp WC, et al. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol 1991;147:22-8.
46. Fleming T, Fleming M, Malek T. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 MAb to granulocyte-differentiation antigen (GR-1) detects members of the Ly-6 family. J Immunol 1993;151: 2399-408.
47. Blumenthal RD, Alisauskas R, Juweid M, Sharkey RM, Goldenberg DM. Defining the optimal spacing between repeat radioantibody doses in experimental models: is there an accurate spacing toxicity endpoint? Cancer 1997;80:2624-35.
48. Macey M, Jiang X, Veys P, McCarthy D, Newland A. Expression of functional antigens on neutropils: effects of preparation. J Immunol Methods 1992;149:37-42.
49. Suzuki T, Muroi K, Tomizuka H, Amemiya Y, Miura Y. Characterization of enriched CD34+ cells from healthy volunteers and those from patients treated with chemotherapy plus granulocyte colony-stimulating factor (G-CSF). Stem Cells 1995;13:273-80.
50. Whetton A, Dexter T. Myeloid hematopoietic growth factors. Biochem Biophys Acta 1994;989:111-32.
51. Cairo M, Suen Y, Sender L, Gillan ER, Ho W, Plunkett JM, et al. Circulating granulocyte colony-stimulating factor (G-CSF) levels after allogeneic and autologous bone marrow transplantation: endogenous G0CSF production correlates with myeloid engraftment. Blood 1992;79:1869-73.
52. Selig C, Northdurft W. Cytokines and progenitor cells of granulopoiesis in peripheral blood of patients with bacterial infections. Blood 1995;79:1869-73.
53. Wagemaker G, Neelis K, Wognum A. Surface markers and growth factor receptors of immature hematopoietic stem cell subsets. Stem Cells 1995;13:165-71.
54. Lisovsky M, Estrov Z, Zhang X, Consoli U, Sanchez-Williams G, Snell V, et al. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood 1996;88:3987-97.
55. Dunn R, Juweid M, Sharkey R, Goldenberg D. Patient specific (PS) estimates of red marrow dose result in improved correlation with myelotoxicity. [abstract]. Soc Nucl Med 1998;45:440.
56. Cluitmans FHM, Esendam BHJ, Veenhof WFJ, Landegent JE, Willemze R, Falkenburg JHF. The role of cytokines and hematopoietic growth factors in the autocrine/paracrine regulation of inducible hematopoiesis. Ann Hematol 1997;75: 27-31.
57. Chopra V, Dinh T, Hannigan E. Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. J Cancer Res Clin Oncol 1997;123:167-72.
58. Chopra V, Dinh T, Hannigan EV. Angiogenin, interleukins, and growth factor levels in serum of patients with ovarian cancer: correlation with angiogenesis. Cancer J Sci Am 1996;2:279-85.
59. Chopra V, Dinh T, Hannigan E. Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest 1998;16:152-9.
60. Domensch J, Linassier C, Gihana E, et al. Prolonged impairment of hematopoiesis after high dose therapy followed by autologous bone marrow transplantation. Blood 1995;85: 3320-7.
61. Talmadge J, Reed E, Ino K, Kessinger A, Kuszynski C, Heimann D, et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant 1997;19:161-72.
62. Shpall E, Cagnoni P, Bearman S, Ross M, Nieto Y, Jones R. Peripheral blood stem cell harvesting and CD34-positive cell selection. Cancer Treat Res 1997;77:143-57.